Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | DGAT1 | O75907 | 3/20 | 0.41 |
| ▸ | BRD4 | O60885 | 1/20 | 0.38 |
| ▸ | CREBBP | Q92793 | 1/20 | 0.38 |
| ▸ | KLKB1 | P03952 | 1/20 | 0.31 |
| ▸ | PNP | P00491 | 2/20 | 0.30 |
| ▸ | USP2 | O75604 | 1/20 | 0.30 |
| ▸ | TSHR | P16473 | 1/20 | 0.30 |
| ▸ | EDNRA | P25101 | 1/20 | 0.30 |
| ▸ | HTR2A | P28223 | 1/20 | 0.30 |
| ▸ | RECQL | P46063 | 1/20 | 0.30 |
| ▸ | BLM | P54132 | 1/20 | 0.30 |
| ▸ | HBB | P68871 | 1/20 | 0.30 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.30 |
| ▸ | MEN1 | O00255 | 1/20 | 0.30 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL20552062 | 0.84 | BRD4 (0.39) | DGAT1BRD4CREBBPPNPUSP2 | |
| SCHEMBL20551665 | 0.80 | BRD4 (0.37) | DGAT1BRD4CREBBPPNPUSP2 | |
| SCHEMBL189854 | 0.79 | BRD4 (0.46) | DGAT1BRD4CREBBPHSD17B10 | |
| SCHEMBL24344409 | 0.78 | MEN1 (0.45) | DGAT1BRD4CREBBPUSP2MEN1 | |
| SCHEMBL19203911 | 0.78 | DGAT1 (0.41) | DGAT1KLKB1 | |
| SCHEMBL15118602 | 0.78 | BRD4 (0.39) | DGAT1BRD4CREBBPPNPUSP2 | |
| SCHEMBL19538828 | 0.77 | BRD4 (0.46) | DGAT1BRD4CREBBPMEN1KMT2A | |
| SCHEMBL15509087 | 0.76 | MEN1 (0.51) | USP2TSHRHSD17B10MEN1KMT2A | |
| SCHEMBL20553727 | 0.76 | BRD4 (0.34) | DGAT1BRD4CREBBP | |
| SCHEMBL23101058 | 0.76 | BRD4 (0.34) | DGAT1BRD4CREBBP |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2909212-B1 | SUBSTITUTED 1,4-DIHYDROPYRAZOLO[4,3-B]INDOLES | TAKEDA PHARMACEUTICALS CO (JP) | 2017-02-22 | — | — | EP | disclosed |
| US-9475816-B2 | Substituted-1,4-dihydropyrazolo[4,3-b]indoles | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2016-10-25 | — | — | US | disclosed |
| US-20150225405-A1 | SUBSTITUTED-1,4-DIHYDROPYRAZOLO[4,3-b]INDOLES | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2015-08-13 | — | — | US | disclosed |
| US-20090306126-A1 | Indole Derivatives | ASTRAZENECA AB (SE) | 2009-12-10 | — | — | US | disclosed |
| EP-2029593-A1 | INDOLE DERIVATIVES | AstraZeneca AB (SE) | 2009-03-04 | — | — | EP | disclosed |
| WO-2007135398-A1 | INDOLE DERIVATIVES | ASTRAZENECA AB (SE) | 2007-11-29 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20150225405-A1 | SUBSTITUTED-1,4-DIHYDROPYRAZOLO[4,3-b]INDOLES | GPR119, RPLP2, FOXM1 | DGAT1 1917/4885BRD4 527/4885CREBBP 1140/4885 |
| US-20090306126-A1 | Indole Derivatives | MTOR, IDO1, AKT1S1 | DGAT1 3242/4885BRD4 1263/4885CREBBP 1649/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.